Metabolic dynamics in chronic gastritis:Examining urinary profiles post Helicobacter pylori eradication

Chronic gastritis is the persistent and insidious inflammation of the gastric lining.Helicobacter pylori(H.pylori)has been identified as the most common cause of chronic gastritis and consequently elimination of H.pylori can lead to its cure.This editorial explores the use of urinary metabolic profiles before and after eradication to identify biomarkers that can aid in prognosis and treatment.Despite providing promising insights,there are limitations such as a small sample size(17 patients),a narrow treatment period of 2 wk,and treatment heterogeneity,which raise concerns.Nevertheless,these findings have opened a gateway to enhancing the treatment and prognosis of chronic gastritis through urinary metabolomics.

Reduced secretion of epidermal growth factor in duodenal ulcer patients with Helicobacter pylori infection

AIM To investigate the concentration changes of epidermal growth factor (EGF) in duodenal ulcer patients with H. pylori infection.

Traditional Chinese herbal medicine plus triple therapy in treating Helicobacter pylori-induced chronic atrophic gastritis: a meta-analysis and cumulative meta-analysis

Objectives:To evaluate the benefits of traditional Chinese herbal medicine(TCHM)plus triple therapy(TT)in the management of Helicobacter pylori(H.pylori)-induced chronic atrophic gastritis(CAG).Methods:A comprehensive access and electronic database search were carried out from inception to June 2020.Prospective randomized trials(TCHM plus TT vs.TT)were selected to assess the eradication rate of H.pylori(ER of H.pylori),clinical symptom relief rate(SRR),treatment-related adverse reactions(TRAR)and 95%confidence intervals(CI)in the meta-analysis and cumulative meta-analysis(CMA).Meta-regression analysis was used to analyze heterogeneity between studies and publication bias.Results:33 studies contained 3,226 participants were included.Compared with the TT group,TCHM plus TT group showed a significantly higher ER of H.pylori(OR=4.14,95%CI:3.21-5.35;P=0.000)and SRR(OR=4.50,95%CI:3.59-5.64).Meanwhile,the TRAR of TCHM plus TT remedy was significantly lower than TT monopoly(RR=0.43,95%CI:0.29-0.64;P=0.000).The results of the CMA,sorted by publication year,duration of treatment,and sample size,confirmed that combined treatment remedy was superior to TT monopoly in respect of ER of H.pylori and SRR.Conclusions:The present study obtained reliable and convincing evidence suggesting that TCHM plus TT remedy was efficacious and safe in treating H.pylori-induced CAG.

History of Helicobacter pylori,duodenal ulcer,gastric ulcer and gastric cancer

Helicobacter pylori (H. pylori) infection underlies gastric ulcer disease, gastric cancer and duodenal ulcer disease. The disease expression reflects the pattern and extent of gastritis/gastric atrophy (i.e., duodenal ulcer with non-atrophic and gastric ulcer and gastric cancer with atrophic gastritis). Gastric and duodenal ulcers and gastric cancer have been known for thousands of years. Ulcers are generally non-fatal and until the 20th century were difficult to diagnose. However, the presence and pattern of gastritis in past civilizations can be deduced based on the diseases present. It has been suggested that gastric ulcer and duodenal ulcer both arose or became more frequent in Europe in the 19th century. Here, we show that gastric cancer and gastric ulcer were present throughout the 17th to 19th centuries consistent with atrophic gastritis being the predominant pattern, as it proved to be when it could be examined directly in the late 19th century. The environment before the 20th century favored acquisition of H. pylori infection and atrophic gastritis (e.g., poor sanitation and standards of living, seasonal diets poor in fresh fruits and vegetables, especially in winter, vitamin deficiencies, and frequent febrile infections in childhood). The latter part of the 19th century saw improvements in standards of living, sanitation, and diets with a corresponding decrease in rate of development of atrophic gastritis allowing duodenal ulcers to become more prominent. In the early 20th century physician’s believed they could diagnose ulcers clinically and that the diagnosis required hospitalization for “surgical disease” or for “Sippy” diets. We show that while H. pylori remained common and virulent in Europe and the United States, environmental changes resulted in changes of the pattern of gastritis producing a change in the manifestations of H. pylori infections and subsequently to a rapid decline in transmission and a rapid decline in all H. pylori-related diseases.

Azithromycin in a triple therapy for H.pylori eradication in active duodenal ulcer

AIM:To assess and compare the efficacy and safety of two triple regimes:A)metronidazole,amoxicillin and omeprazole, which is still widely used in Russia,and B)azithromycin, amoxicillin and omeprazole in healing active duodenal ulcer and H.pylori eradication. METHODS:100 patients with active duodenal ulcer were included in the open,multicentre,randomized study with comparative groups.Patients were randomly assigned to one of the following one-week triple regimes:A) metronidazole 500 mg bid,amoxicillin I g bid and omeprazole 20 mg bid(OAM,n=50)and B)azithromycin 1 god for the first 3 days(total dose 3 g),amoxicillin 1 g bid and omeprazole 20 mg bid(OAA,n=50).Omeprazole 20 mg od was given after the eradication course as a monotherapy for three weeks.The control endoscopy was performed 8 weeks after the entry.H.pyloriinfection was determined in the entry of the study and four weeks after the cessation of treatment by means of histology and CLO-test. RESULTS:97 patients completed the study according to the protocol(1 patient of the OAM group did not come to the control endoscopy,2 patients of the OAA group stopped the treatment because of mild allergic urticaria).Duodenal ulcers were healed in 48 patients of the OAM group(96 %, C190.5-100 %)and in 46 patients of the OAA group(92 %, CI 89.5-94.5 %)(p=ns).H.pyloHinfection was eradicated in 15 out of 50 patients with OAM(30 %,CI 17-43 %)and in 36 out of 50 patients treated with OAA(72 %;CI 59-85 %) (P<0.001)-ITT analysis.CONCLUSION: The triple therapy with omeprazole, amoxicillin and metronidazole failed to eradicate H.pylori'vc\ the majority of patients, which is an essential argument to withdraw this regimen out of the national recommendations. Macrolide with amoxicillin are preferable to achieve higher eradication rates. Azithromycin (1 g od for the first 3 days) can be considered as a successful component of the triple PPI-based regimen.

Comparison of sequential and 7-,10-,14-d triple therapy for Helicobacter pylori infection

AIM:To compare the effectiveness of sequential therapy for Helicobacter pylori(H.pylori) infection with that of triple therapy of varying durations.METHODS:The 460 patients enrolled in this study had H.pylori-associated gastritis or a gastric or duodenal ulcer.After screening,H.pylori-infected patients were randomly assigned to receive either conventional triple therapy for 7,10 or 14 d,or a new 10-d sequential therapy.Each of the 4 treatment groups included 115 patients.The outcomes of eradication therapy were assessed 4 wk after treatment by the urea breath test and histology.RESULTS:The overall eradication rate was 81.0%,and eradication rates were 75.7% for 7-d conventional triple therapy,81.9% for 10-d conventional triple therapy,84.4% for 14-d conventional triple therapy,and 82.0% for 10-d sequential therapy.Neither intention-to-treat analysis nor per protocol analysis showed significant differences in eradication rates using sequential therapy or the standard triple therapy(P = 0.416 and P = 0.405,respectively).CONCLUSION:There are no significant differences between 10-d sequential eradication therapy for H.pylori and any duration of standard triple treatment in Korean patients.

Characteristics of gastric cancer in peptic ulcer patients with Helicobacter pylori infection

AIM:To evaluate the incidence and clinical characteristics of gastric cancer(GC) in peptic ulcer patients with Helicobacter pylori(H.pylori) infection.METHODS:Between January 2003 and December 2013, the medical records of patients diagnosed with GC were retrospectively reviewed.Those with previous gastric ulcer(GU) and H.pylori infection were assigned to the Hp GU-GC group(n = 86) and those with previous duodenal ulcer(DU) disease and H.pylori infection were assigned to the Hp DUGC group(n = 35).The incidence rates of GC in the Hp GU-GC and Hp DU-GC groups were analyzed.Data on demographics(age, gender, peptic ulcer complications and cancer treatment), GC clinical characteristics [location, pathological diagnosis, differentiation, T stage, Lauren's classification, atrophy of surrounding mucosa and intestinal metaplasia(IM)], outcome of eradication therapy for H.pylori infection, esophagogastroduodenoscopy number and the duration until GC onset were reviewed.Univariate and multivariate analyses were performed to identify factors influencing GC development.The relative risk of GC was evaluated using a Cox proportional hazards model.RESULTS:The incidence rates of GC were 3.60%(86/2387) in the Hp GU-GC group and 1.66%(35/2098) in the Hp DU-GC group.The annual incidence was 0.41% in the Hp GU-GC group and 0.11% in the Hp DUGC group.The rates of moderate-to-severe atrophy of the surrounding mucosa and IM were higher in the Hp GU-GC group than in the Hp DU-GC group(86% vs 34.3%, respectively, and 61.6% vs 14.3%, respectively, P < 0.05).In the univariate analysis, atrophy of surrounding mucosa, IM and eradication therapy for H.pylori infection were significantly associated with the development of GC(P < 0.05).There was no significant difference in the prognosis of GC patients between the Hp GU-GC and Hp DU-GC groups(P = 0.347).The relative risk of GC development in the Hp GUGC group compared to that of the Hp DU-GC group,after correction for age and gender,was 1.71(95%CI:1.09-2.70;P=0.02).CONCLUSION:GU patients with H.pylori infection had higher GC incidence rates and relative risks.Atrophy of surrounding mucosa,IM and eradication therapy were associated with GC.

Association of Helicobacter pylori IgA antibodies with the risk of peptic ulcer disease and gastric cancer

AIM: To compare the prevalence of Helicobacter pylori (Hpylori) IgG and IgA antibodies between adult subjects,with defined gastric diseases, nondefined gastric disorders and those representing the population.METHODS: Data on H pylori IgG and IgA antibodies,determined by enzyme immunoassay, were analyzed in 3 252 subjects with DGD including 482 patients with gastric ulcer, 882 patients with duodenal ulcer, 1 525patients with chronic gastritis only and 363 subjects with subsequent gastric cancer, 19 145 patients with NoDg and4 854 POPUL subjects. The age-adjusted prevalences were calculated for 1- and 20-year age cohorts.RESULTS: The prevalences of IgG antibodies were equally high (89-96%) in all 20-year age cohorts of the DGD groups, whereas the prevalences of IgG antibodies were lower and increased by age in the POPUL and NoDg groups. The prevalences of IgA antibodies were also higher in the DGD groups; among them CA (84-89%) and GU groups (78-91%) showed significantly higher prevalences than DU (68-77%) and CG patients (59-74%) (OR 2.49, 95%CI 1.86-3.34 between the GU and DU groups). In the CA, GU, and DU groups, the IgA prevalences showed only minor variation according to age, while they increased by age in the CG, POPUL, and NoDg groups (P≤0.0001). The IgA response, but not the IgG response, was associated with an increased risk of CA (OR 2.41, 95%CI 1.79-3.53) and GU (OR 2.57,95%CI 1.95-3.39) in comparison with CG patients.CONCLUSION: An IgA antibody response during H pylori infection is significantly more common in CA and GU patients as compared with CG patients.

Low eradication rate of Helicobacterpyloriwith triple 7-14 days and quadriple therapy in Turkey

AIM:The eradication rate of Helicobacter pylori (H pylori) shows variation among countries and regimens of treatment. We aimed to study the eradication rates of different regimens in our region and some factors affecting the rate of eradication. METHODS:One hundred and sixty-four H pylori positive patients (68 males,96 females;mean age:48±12 years) with duodenal or gastric ulcer without a smoking history were included in the study.The patients were divided into three groups according to the treatment regimens.Omeprazole 20mg,clarithromycin 500mg,amoxicillin 1g were given twice daily for 1 week (Group Ⅰ) and 2 weeks (Group Ⅱ). Patients in Group Ⅲ received bismuth subsitrate 300mg, tetracyline 500mg and metronidazole 500mg four times daily in addition to Omeprazole 20mg twice daily.Two biopsies each before and after treatment were obtained from antrum and corpus,and histopathologically evaluated. Eradication was assumed to be successful if no H pylorus was detected from four biopsy specimens taken after treatment.The effects of factors like age,sex,H pylori density on antrum and corpus before treatment,the total H pylori density,and the inflammation scores on the rate of H pylori eradication were evaluated. RESULTS:The overall eradication rate was 42%.The rates in groups Ⅱ and Ⅲ were statistically higher than that in group Ⅰ (P<0.05).The rates of eradication were 24.5%, 40.7% and 61.5% in groups Ⅰ,Ⅱ and Ⅲ,respectively.The eradication rate was negatively related to either corpus H pylori density or total H pylori density (P<0.05).The median age was older in the group in which the eradication failed in comparison to that with successful eradication (55 yr vs 39 yr,P<0.001).No correlation between sex and H pylori eradication was found. CONCLUSION:Our rates of eradication were significantly lower when compared to those reported in literature.We believe that advanced age and high H pylori density are negative predictive factors for the rate of H pylori eradication.

Observation of the Effect of Triple Therapy on Duodenal Ulcer with HP Posity

Thirty-foar cases of duodenal ulcer with Hp osity weve treated with Ompeperazole, Amoxi-cillin and Tindazole, which were compared with 34 cases of Hp positive duodenal ulcer treated with omeperazole only. The duration of treatment were both one week and all the patients were re-examed at one month after treatment. The result showed that the huring rate of ulcers (HRU) in triple therapy group was 88. 2%, uhile that of the contr group was 82. 3%. No significant difference was observed in the two groups (p>0.05). Hp eradication rate (HER) in triple therapy group was 91. 7%, while that of the control group was 41. 1 %. There was significant difference between the HERs of the two gronps (p<0.01 ). In the 45 cases with Hp eradication, ulcers in 44 cases hared, with huring rate of 97. 8%. In the 23cases without Hp eradication, ulcers in 14 cases hured, with huring rate of 60. 9%. There was significant difference between these two gronps (p<0.05), which suggested the significant improvement of HRU of-ter Hp eradication. The triple therapy has the advantages such as high HRU, high rate of tolerance and no severe side effects. The therapy deserve recomrnendation clinically.

Modified sequential therapy vs quadruple therapy as initial therapy in patients with Helicobacter infection

AIM: To evaluate the efficacy and safety of modified sequential therapy and to compare modified sequential therapy with standard quadruple therapy for Helicobacter pylori(H. pylori) eradication.METHODS: In total, 200 consecutive patients who were diagnosed with H. pylori-infected chronic gastritis by electronic endoscopy and rapid urease testing from December 2012 to October 2013 were enrolled in this study. The patients had not previously received H. pylori eradication treatment, and were randomized into two groups. The patients in Group A(n = 101) were treated with ilaprazole + bismuth potassium citrate + amoxicillin and clavulanate potassium + levofloxacin, and the patients in Group B(n = 99) were administered a modified sequential therapy composed of ilaprazole at 5 mg bid and amoxicillin and clavulanate potassium at 914 mg for the first five days followed by ilaprazole at 5 mg bid, furazolidone at 100 mg bid and levofloxacin at 500 mg qid for the next five days. Four to six weeks after the end of treatment, a 14C-urea breath test was performed for all the subjects to confirm the eradication of H. pylori. The intention-to-treat and per-protocol eradication rates were determined.RESULTS: A total of 190 of the 200 patients completed the study. All 200 patients were included in the intention-to-treat analysis, whereas 190 patients were included in the per-protocol analysis. In the intentionto-treat analysis, the rates of H. pylori eradication in Groups A and B were 85.15%(86/101) and 81.82%(81/99), respectively. In the per-protocol analysis, the H. pylori eradication rates in Groups A and B were 88.66%(86/97) and 87.09%(81/93), respectively. No significant difference was observed(χ2 = 0.109, P = 0.741) in the eradication rate between Groups A and B. The rates of adverse effects observed in the groups were similar at 6.19%(6/97) for Group A and 7.53%(7/93) for Group B(P > 0.05). No mortality or major morbidities were observed in any of the patients. Symptomatic improvements in the presentation of stomachache, acid regurgitation, and burning sensation were not significantly different between the two groups.CONCLUSION: Ilaprazole-based 10-d standard quadruple therapy does not offer an incremental benefit over modified sequential therapy for the treatment of H. pylori infection, as both treatment regimens appear to be effective, safe, and well-tolerated as initial treatment options.

Kang Wei Granules in Treatment of Gastropathy Related to Helicobacter Pylori Infection

Kang Wei Granules,a granular preparation for strengthening the spleen and replenishing Qi and for clearing away heat and resolving dampness,was used in the treatment of 288 cases of gastropathy related to Helicobacter pylori infection.The effects were compared with De Nol^(?) triple therapy in the control group of 74 cases.The therapeutic results showed that Kang Wei Granules was superior to the western drugs in improving the principal symptoms of deficiency of the spleen and stomach,and retention of damp-heat in the interior (P<0.05).

Helicobacter Pylori Infection: Epidemiological, Clinical and Endoscopic Aspects in Brazzaville

Introduction: Helicobacter pylori infection is a real health problem worldwide. It is the most common chronic bacterial infection in the world, and is particularly prevalent in developing countries. Objective: To determine the frequency of Helicobacter pylori infection and to study the epidemiological, clinical and endoscopic characteristics associated with this infection in Brazzaville. Patients and Methods: This was a descriptive cross-sectional study conducted from January to November 2020, i.e. 11 months. This work focused on 100 symptomatic patients over 18 years old referred for upper GI endoscopy. Gastric biopsies for biological study by urease test and molecular study by real time PCR technique were taken. Results: With a mean age of 46.32 ± 15.20 years, the frequency of Hp infection was 91%, with a female predominance of 53%. The sex ratio was 0.92. The average age was 46.32 ± 15.20 years. Carriage of the infection was more important in households with more than 3 persons, in patients consuming public tap water and in those using both types of sanitary facilities. Endoscopy was indicated for epigastralgia in 93.1% of cases. About 56.14% of the infected patients had normal mucosa versus 12.28% with ulcerated lesions and 22.81% with gastritis. Conclusion: The prevalence of Helicobacter pylori infection is significant in Congo, justifying early detection in order to improve management.

胃复春联合四联疗法治疗H.pylori相关性慢性非萎缩性胃炎临床疗效观察

目的观察胃复春联合四联疗法对幽门螺杆菌(Helicobacter pylori,H.pylori)相关性慢性非萎缩性胃炎的治疗效果.目的选取196例H.pylori相关性慢性非萎缩性胃炎患者,随机分为治疗组(胃复春联合四联疗法)99例和对照组(四联疗法)97例,比较2组患者治疗后的临床症状和胃镜改善情况以及H.pylori根除率.结果治疗组患者症状总有效率、胃镜总有效率和H.pylori根除率均高于对照组(93.9%vs85.6%,91.9%vs 84.5%,92.9%vs 83.5%),疗效明显优于对照组,差异具有统计学意义(P<0.05).结论胃复春联合四联疗法治疗H.pylori相关性慢性非萎缩性胃炎疗效优于单纯四联疗法,可提高H.pylori根除率,值得在临床推广使用.

柴芍胃康汤联合四联疗法治疗肝胃气滞证Hp阳性慢性萎缩性胃炎的疗效观察

目的:观察柴芍胃康汤联合四联疗法治疗肝胃气滞证幽门螺杆菌(Hp)阳性慢性萎缩性胃炎(CAG)的疗效及对患者胃泌素-17(G-17)、丙二醛(MDA)、胃蛋白酶原(PG)Ⅰ和PGⅡ水平,胃黏膜组织病理和Hp根除的影响。方法:选取2021年6月至2023年5月该院收治的肝胃气滞证Hp阳性CAG患者140例,按随机数字表法分为联合组和对照组(各70例)。对照组患者给予标准四联疗法,联合组患者在对照组的基础上给予柴芍胃康汤治疗。比较两组患者治疗前后血清G-17、MDA、PGⅠ和PGⅡ水平,胃黏膜组织病理评分、Hp根除率,观察安全性和临床疗效。结果:治疗后,两组患者血清G-17、PGⅠ水平明显升高,MDA、PGⅡ水平和胃黏膜组织病理评分明显降低;且联合组患者血清G-17、PGⅠ水平较对照组升高,MDA、PGⅡ水平和胃黏膜组织病理评分较对照组降低,差异均有统计学意义(P<0.05)。联合组患者的Hp根除率、总有效率分别为92.86%(65/70)、92.86%(65/70),明显高于对照组的81.43%(57/70)、81.43%(57/70),差异均有统计学意义(P<0.05)。结论:柴芍胃康汤联合四联疗法治疗肝胃气滞证Hp阳性CAG的疗效较好,可改善患者胃功能、氧化应激和胃黏膜组织病理损伤,并可有效提高Hp根除率。

穴位埋线辅助四联疗法治疗脾胃虚弱型慢性萎缩性胃炎伴Hp感染临床研究

目的:观察穴位埋线辅助四联疗法治疗脾胃虚弱型慢性萎缩性胃炎(CAG)伴幽门螺杆菌(Hp)感染的临床疗效。方法:选取112例脾胃虚弱型CAG伴Hp感染患者,采用随机数字表法分为对照组(予四联疗法治疗)和观察组(予穴位埋线辅助四联疗法治疗)各56例。治疗结束后,2组均随访5个月。比较2组临床疗效、胃黏膜功能指标[胃泌素17(G-17)、胃蛋白酶原Ⅰ(PGⅠ)]、健康调查简表(SF-36)评分、中医证候积分、病理评分、不良反应发生率及复发率。结果:总有效率观察组96.43%,高于对照组80.36%(P<0.05)。治疗后3个月,2组血清G-17、PGⅠ水平均较治疗前升高(P<0.05),观察组上述2项指标水平均高于对照组(P<0.05)。治疗后1个月、3个月,2组SF-36评分均较治疗前升高(P<0.05),观察组SF-36评分均高于同期对照组(P<0.05)。治疗后3个月,2组中医证候积分均较治疗前降低(P<0.05),观察组中医证候积分低于对照组(P<0.05)。治疗后5个月,2组病理评分均较治疗前下降(P<0.05),观察组病理评分低于对照组(P<0.05)。不良反应发生率观察组8.93%,与对照组3.57%比较,差异无统计学意义(P>0.05)。治疗后5个月,复发率观察组1.85%,低于对照组15.56%(P<0.05)。结论:穴位埋线辅助四联疗法治疗脾胃虚弱型CAG伴Hp感染,可减轻患者的临床症状,改善胃黏膜功能,提高生活质量,降低复发率,且安全性好。

中西医结合治疗幽门螺杆菌相关性胃炎临床观察

目的:观察丹栀逍遥散合左金丸加减治疗幽门螺杆菌相关性胃炎的临床疗效。方法:将128例幽门螺杆菌相关性胃炎患者随机分为两组各64例,对照组予雷贝拉唑钠肠溶片、克拉霉素片、阿莫西林胶囊、枸橼酸铋钾胶囊治疗;治疗组在对照组基础上加用丹栀逍遥散合左金丸加减治疗。结果:治疗组幽门螺杆菌根除率为96.88%,明显高于对照组的81.25%,两组比较差异有统计学意义(P<0.05);治疗组总有效率96.88%,明显高于对照组的85.94%,两组比较差异有统计学意义(P<0.05);治疗组复发率1.56%,明显低于对照组的9.38%,两组比较差异有统计学意义(P<0.05)。结论:丹栀逍遥散合左金丸加减治疗幽门螺杆菌相关性胃炎临床疗效较好。

兰索拉唑、阿莫西林二联疗法治疗幽门螺杆菌相关性慢性胃炎的疗效分析

目的 探讨对幽门螺杆菌(Hp)相关性慢性胃炎患者给予兰索拉唑、阿莫西林二联疗法治疗后获得的临床疗效。方法 120例Hp相关性慢性胃炎患者,以投掷硬币法分为参照组和研究组,每组60例。参照组患者施以兰索拉唑治疗,研究组患者施以兰索拉唑、阿莫西林二联疗法治疗。比较两组患者炎症因子水平[白细胞介素-8(IL-8)、白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)]、Hp清除率、复发率以及不良反应(口苦、胃肠道反应、皮肤反应以及头晕)发生率。结果 治疗后,研究组患者IL-8、IL-6、TNF-α水平分别为(7.63±1.32)ng/L、(16.39±3.22)ng/L、(1.21±0.42)μg/ml,显著低于参照组的(9.39±1.55)ng/L、(34.52±13.49)ng/L、(1.85±0.53)μg/ml(P<0.05)。研究组患者Hp清除率98.33%(59/60)高于参照组的81.67%(49/60),复发率1.67%(1/60)低于参照组的13.33%(8/60)(P<0.05)。研究组患者不良反应发生率5.00%与参照组的3.33%比较,未呈现出明显差异(P>0.05)。结论 临床对Hp相关性慢性胃炎患者在治疗期间应用兰索拉唑+阿莫西林二联疗法,可将患者的炎症因子水平显著改善,同时将Hp清除率提高,将复发率降低,并且不会导致口苦、胃肠道反应、皮肤反应以及头晕等不良反应增加,疗效显著。

半夏泻心汤加味联合四联疗法对脾胃湿热型Hp相关慢性胃炎患者Hp清除率及胃肠黏膜功能的影响

[目的]探究半夏泻心汤加味联合四联疗法对脾胃湿热型幽门螺杆菌(Hp)相关慢性胃炎患者Hp清除率及胃肠黏膜功能的影响。[方法]收集2020年3月-2022年3月在本院收治的92例脾胃湿热型Hp相关慢性胃炎患者,将患者按照随机法分为对照组45例、研究组47例。对照组患者采用四联疗法予以治疗,而研究组患者则是在对照组的基础上联合半夏泻心汤加味进行治疗,比较两组患者的Hp清除率、胃肠黏膜功能、中医证候积分、胃肠道激素、临床疗效的情况变化。[结果]治疗后两组患者主症、次症积分、丙二醛(MDA)、血管活性肠肽(VIP)表达水平降低,胃泌素-17(GAS-17)、血清胃蛋白酶原I(PGI)、前列腺素E_(2)(PGE_(2))、胃动素、瘦素表达水平升高,且研究组较对照组有所改善(P<0.05)。与对照组比较,研究组的Hp清除率、临床总有效率升高(P<0.05)。研究组的临床总有效率比对照组高(P<0.05)。[结论]半夏泻心汤加味联合四联疗法对治疗脾胃湿热型Hp相关慢性胃炎患者效果显著,可有效减轻患者的中医症状,提升Hp清除率,调节体内的肠道菌群,改善胃肠黏膜功能,值得临床应用。

中医药治疗幽门螺杆菌感染性慢性胃炎研究进展

中医学认为幽门螺杆菌(helicobacter pylori, Hp)感染性慢性胃炎(以下简称Hp胃炎)的基本病机是脾胃虚弱为本,湿邪阻滞为标。中医药治疗Hp胃炎的实验研究包括抗Hp的机制、单药和复方研究,临床研究包括抗Hp的中药复方、中成药和联合疗法研究。目前的研究存在以下问题:(1)中医辨证证型及疗效评估标准尚未完全统一,导致研究结论缺乏说服力;(2)治疗方法多为医家自拟方药或经验总结,难以形成统一、确切的诊疗标准;(3)现有研究多为临床对照试验,存在样本量小、随机对照不严格等弊端;(4)缺少高质量的动物实验和细胞实验,且存在菌株选择、实验方法混乱等问题。未来的研究可考虑:(1)继续开展多中心、大样本、高质量的临床研究;(2)严格设计动物实验和细胞实验,并需提前确立实验标准;(3)在复方研究的同时,完善中药活性成分提取及分析,进一步明确中药的药理机制。